尊龙凯时人生就是搏·(中国区)官方网站
About Us
About Sino Biopharm
Board of Directors
Senior Management
R&D
R&D Team
Products
Product List
Sustainability
ESG Governance
ESG Management Practices
ESG Reports
Investors
Information Disclosure
Corporate Governance
Presentation
Investor FAQ
Notices
News
Press Releases
Contact
CN
EN
Investors
Home
>
Investors
>
Information Disclosure
Information Disclosure
Corporate Governance
Presentation
Investor FAQ
Notices
Information Disclosure
VOLUNTARY ANNOUNCEMENT - “COLESEVELAM HYDROCHLORIDE TABLETS” OBTAINED ANDA APPROVAL
2022.03.15
POSITIVE PROFIT ALERT
2022.03.15
VOLUNTARY ANNOUNCEMENT - "LURASIDONE HYDROCHLORIDE TABLETS" OBTAINED DRUG REGISTRATION CERTIFICATE
2022.03.14
VOLUNTARY ANNOUNCEMENT - “IGURATIMOD” API OBTAINED REGISTRATION CERTIFICATE FROM PMDA
2022.03.11
VOLUNTARY ANNOUNCEMENT - ENTERING INTO COOPERATIVE DEVELOPMENT AGREEMENT FOR FULLY HUMAN ANTIBODY DRUGS
2022.03.11
VOLUNTARY ANNOUNCEMENT - "SITAGLIPTIN PHOSPHATE TABLET" OBTAINED DRUG REGISTRATION CERTIFICATES
2022.03.10
VOLUNTARY ANNOUNCEMENT - "TOFACITINIB CITRATE TABLET" OBTAINED DRUG REGISTRATION CERTIFICATE
2022.03.10
VOLUNTARY ANNOUNCEMENT - "TDI01" SUSPENSION OBTAINED APPROVAL FOR PNEUMOCONIOSIS CLINICAL TRIAL
2022.03.08
首页
上一页
40
41
42
43
44
45
...
53
尾页
下一页